HeyJaredProsper Junior Bakiny
- Indexed articles, last 90 days
- 66
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Aol
- Top 5K sites
- Earliest in this view
- Aug 26, 2026
Latest articles
Nvidia Just Gave Investors 150 Billion Reasons to Buy the Stock - AOL (opens the original)
Read excerpt
Nvidia recently announced a substantial share repurchase authorization increase. The company can afford it, given how much cash it generates. Nvidia can still beat the market as it continues to ride the AI revolution. These 10 stocks could mint the next wave of millionaires › Nvidia (NASDAQ:NVDA) has crushed broader equities over the past five years thanks to its position in the artificial intelligence (AI) industry. There are plenty of debates on Wall Street over whether the semiconductor speci
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy - AOL (opens the original)
Read excerpt
Novo Nordisk could strengthen its obesity pipeline by buying out Kailera Therapeutics and Viking Therapeutics. These two biotechs boast highly promising mid and late-stage programs. Even without acquisitions, Novo could have a significantly improved approved portfolio within a few years. 10 stocks we like better than Novo Nordisk › Novo Nordisk(NYSE: NVO) has a problem. The company generates most of its revenue from its diabetes and obesity products, but stiff competition from Eli Lilly(NYSE: LL
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - AOL (opens the original)
Read excerpt
Viking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. The medicine could eventually become a notable player in the weight-loss market. Viking Therapeutics' prospects look promising, but there are significant risks to consider. 10 stocks we like better than Viking Therapeutics › Investors looking to capitalize on the rapidly expanding weight loss drug market have increasingly more options. Eli Lilly(NYSE: LLY) and Novo Nordisk(NYSE: NVO) are still the lea
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High - AOL (opens the original)
Read excerpt
Johnson & Johnson has a deep and diversified pharmaceutical portfolio. The company's robotic surgical system, Ottava, could become a meaningful growth driver. Johnson & Johnson has a fantastic dividend track record. 10 stocks we like better than Johnson & Johnson › Johnson & Johnson(NYSE: JNJ) seems to be firing on all cylinders. The company's financial results have been strong this year, leading to a solid stock market performance. Johnson & Johnson's shares aren't too far from their all-time h
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? - AOL (opens the original)
Read excerpt
Roche's leading weight loss and diabetes candidate has posted excellent Phase 2 clinical trial results. The medicine could carve out a solid niche in this field. Roche may still not be able to take the lead from Eli Lilly, but there are other reasons to invest in the company. 10 stocks we like better than Roche Holding AG › Novo Nordisk(NYSE:NVO) has been a pioneer in the market for weight loss drugs, but Eli Lilly(NYSE:LLY) has since emerged as the leader. Both drugmakers have deep pipelines th
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5K sites
For Aol, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.